Consilient Health Limited Announces Board Changes

Consilient Health is pleased to announce the appointment of Mr John Dixon as Non-Executive Director of the Company.

John joined the pharmaceutical industry in 1974 and, from 1982, remained with Boehringer Ingelheim. During that time John is well known for heading up the Global Respiratory Marketing function and for launching BI’s first ever blockbuster “Spiriva” for chronic obstructive pulmonary disease (COPD) with peak sales of €5 billion. John later took up the post of Managing Director in Australia and New Zealand before returning to the UK where he held the position of Managing Director for the UK and Ireland before retiring from BI at the end of 2013.

Commenting on his appointment John said, “I am very pleased to be joining the Consilient Health board and supporting all our efforts to develop and grow the total business. The addition of Innovative Medicines to Consilient Health’s current strong portfolio will strengthen our overall business profile. I am looking forward to working with all the teams to create successful strategies and overcome challenges as we move forward in our commercial development.”

Consilient Health’s board looks forward to benefiting from the wisdom and support of John Dixon to continue to develop its business at this exciting time for the company.

Due to his other commitments, Mr Harry Stratford OBE (who has served as a Non-Executive Director since January 2015) has decided to step down from the Consilient Health board. The board is very grateful to Harry for all his guidance and support over the last three years and wishes him well for the future.

About Consilient Health

Consilient Health is a pharmaceutical company focused on the insightful, innovative commercialisation of medicines in Europe and the Middle East: our capabilities include everything from regulatory affairs through to market access, supply chain, distribution, marketing and sales all underpinned by quality and compliance. Our current therapeutic focus is women’s health, urology and endocrinology. Consilient Health markets prescription medicines, choosing products where there is a clear commercial opportunity and an unmet clinical need.

The Company seeks to build long term collaborations with its partners and believes in transparent communication to ensure long-term, mutually beneficial relationships. Our partners are pharma companies who develop and manufacture medicines and innovative healthcare solutions but who lack a physical presence, know-how or desire to commercialise them in Europe and the Middle East. Our capabilities allows these companies to increase the geographic reach of their products and optimise revenue whilst minimising risk and as an independent business, Consilient Health can upscale to suit the needs of patients, prescribers, payers and partners.

The Company is headquartered in Ireland, with operations in the UK, Sweden (for the Nordics), and the UAE (for the Middle East), as well as additional partnerships in Europe.

For more information, please visit www.consilienthealth.com

UK/CH/0418/0023
Date of preparation: 12th April 2018